FIMM – Institute for Molecular Medicine Finland is a translational research institute focusing on human genomics and precision medicine as part of the Helsinki Institute of Life Science HiLIFE at the University of Helsinki.
Role within NeuroCOV
FIMM is responsible for epidemiological characterization of NeuroCOVID including the identification of neurological conditions emerging in COVID-19 patients and their prevalence rates. In particular, together with the University of Umeå, FIMM will form nation-wide register-based cohorts to investigate neurological consequences in COVID-19 patients and in the offspring of mothers that were tested COVID-19 positive. Furthermore, we will take part in developing individual prediction models for NeuroCOVID risk by combining clinical and genetic data.
